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Abstract: Objective: Our aim is to assess the effective factors on hospitalization costs of COVID-19 patients.
Methods: Data related to clinical characteristics and cost of hospitalized COVID-19 patients from February 2020
until July 2020, in a public teaching hospital in Tehran, Iran was gathered in a retrospective cohort study. The
corresponding factors influencing the diagnostic and therapeutic costs were evaluated, using a generalized lin-
ear model.
Results: The median COVID-19 related diagnostic and therapeutic costs in a public teaching hospital in Iran,
for one hospitalized COVID-19 patient was equal to 271.1 US dollars (USD). In patients who were discharged
alive from the hospital, the costs increased with patients’ pregnancy (P<0.001), loss of consciousness during
hospitalization (P<0.001), a history of drug abuse (P=0.006), history of chronic renal disease (P<0.001), end
stage renal disease (P=0.002), history of brain surgery (P=0.001), history of migraine (P=0.001), cardiomegaly
(P=0.033) and occurrence of myocardial infarction during hospitalization (P<0.001). In deceased patients, low
age P<0.001), history of congenital disease (P=0.024) and development of cardiac dysrhythmias during hospital-
ization (P=0.044) were related to increase in therapeutic costs.
Conclusion: Median diagnostic and therapeutic costs in COVID-19 patients, hospitalized in a public teaching
hospital in Iran were 271.1 USD. Hoteling and medications made up most of the costs. History of cardiovascular
disease and new onset episodes of such complications during hospitalization were the most important factors
contributing to the increase of therapeutic costs. Moreover, pregnancy, loss of consciousness, and renal diseases
are of other independent factors affecting hospitalization costs in COVID-19 patients.
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1. Introduction
With daily increase in the number of infected people with
SARS-CoV-2 worldwide, health care systems across the globe
have been under immense pressure and have faced a short-
age of hospital beds (1, 2). Most of medical procedures have
been delayed due to the risk of infection in hospitals and
also to provide more hospital beds for COVID-19 patients (3).
In these troubling times, the sources of hospitals have been
limited, their costs for providing personal protective equip-
ment (PPE) have increased and they have faced problems
in salary payments for healthcare workers (4). On the other
hand, the costs forced on the patients, their families and also
the healthcare system have increased. Taking into consider-
ation the various reports showing COVID-19 serious compli-
cations, e.g., neurological, cardiovascular, renal and gastroin-
testinal involvement (5-7), hospitalization period has been
prolonged in patients with underlying diseases and these
groups of patients have needed more measures in hospitals,
and thus faced increase in their hospitalization costs (8, 9).
There are currently a small number of studies evaluating the
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hospitalization costs of COVID-19 patients and it is not yet
clear which underlying and clinical factors have the most im-
pact on patients’ expenditure. Whereas, the knowledge of
healthcare decision makers about costly medical diagnos-
tic and therapeutic procedures, can lead to a more effective
patient management and better allocation of resources for
hospitals and healthcare centers for treatment of COVID-19.
Since there are no comprehensive studies regarding the mat-
ter, our aim is to assess the factors responsible for hospital-
ization costs, especially underlying conditions.
2. Methods
2.1. Study design
In order to gather the data needed for this cross-sectional
study, medical files of COVID-19 patients who were hospital-
ized from 18th of February until 20th of July 2020, in Imam
Hossein Hospital Center, Tehran, Iran, were gathered from
the hospital registry system. Imam Hossein Hospital is a
teaching public hospital, in which patients’ medical costs are
based on governmental tariffs. This study was approved by
Shahid Beheshti university of medical sciences ethic com-
mittee (Code: IR.SBMU.RETECH.REC.1399.683).
2.2. Study sample
The hospitalization costs of COVID-19 patients, whose dis-
ease was proved by a positive RT-PCR, were included. Pa-
tient files which didn’t have the variables of this study or had
incomplete data about hospitalization costs were excluded
from the study.
2.3. Variables
The evaluated data were patients’ demographic information,
history of cardiovascular disease, history of other concomi-
tant disease, symptoms at the time of admission, labora-
tory and radiological findings, previous medications, devel-
opment of cardiovascular complications and hospital costs.
Total hospitalization costs were recorded as Iranian Rials,
and by using the exchange rate during the period of this
study, were presented as US dollar (USD). Using Iranian Cen-
tral Bank data, the mean exchange rate of USD to Iranian Ri-
als during study period was 169814 Iranian Rials. Therefore,
we divided total hospitalization cost by 169814, to report the
data as USD.
The costs are split into 6 groups in this study. These costs
include hoteling and nursing, drug, physician services, lab-
oratory services and imaging services’ costs. The sum of all
costs during hospital stay was also recorded.
2.4. Statistical analysis
All analyses were done with STATA 14.0 analytical program.
Quantitative data are reported as median and interquartile
range (IQR), and qualitative data are reported as frequency
and percentage. Since data distribution was not normal, the
analyses were done using generalized linear model (GLM)
with a gamma distribution and log link function. GLM with a
gamma distribution is a common method in analysis of dis-
ease related cost (10, 11). Firstly, the possible factors effec-
tive on hospitalization costs were determined using univari-
ate GLM analysis. Then, the variables with a P-value less than
0.1 in univariate analysis, were entered into a stepwise mul-
tivariate GLM model in order to determine the independent
factors effecting the hospitalization costs. The results are re-
ported as coefficient and 95% confidence interval (95% CI).
The significance level was considered to be P<0.05.
3. Results
3.1. Patients’ characteristics
From February until July 2020, data related to 991 COVID-19
patients were extracted from Imam Hossein Hospital’s reg-
istry system. 54.9% of patients were male and 46.7% were
over 65 years of age. In this time period, 256 patients (25.8%)
passed away. The median and IQR of total therapeutic costs
in alive and deceased patients were 254.5 (165.2-428.0) and
380.8 (194.6-765.0) USD, respectively. The median total cost
was estimated to be 271.1 (170.7-489.6) USD.
3.2. Hospitalization costs in alive COVID-19 pa-
tients
A review of therapeutically costs of 735 patients, who were
discharged from the hospital, showed that the most of the
patients’ costs were related to hoteling and nursing services
(median=109.5; IQR: 64.4-17.5 USD) and after that drug re-
lated costs (median=33.9; IQR: 17.5-77.6 USD), laboratory
services (median=52.6; IQR: 39.1-76.1 USD), medical services
(median=40.2; IQR: 25.2-70.7 USD), and imaging services
(median=7.0; IQR: 4.2-12.9 USD) had the highest hospitaliza-
tion costs (Figure 1).
Table 1 shows the therapeutic costs (as median and IQR)
stratified by underlying and clinical variables. The highest
cost was observed in patients between 10-24 years of age
(309 [203.2-468.2]) and patients with body mass index greater
or equal to 40 kg/m2 (321.6 [165.2-454.9]). The hospitaliza-
tion costs of pregnant patients or patients who developed
loss of consciousness during hospital stay was higher than
other patients (382.4 [282.4-786.7] and 458.3 [198.4-789.3],
respectively). Hospitalization costs of patients who had pre-
vious history of COVID-19 (467.5 [224.7-716.5]), drug (616.7
[201.6-764.7]) and alcohol abuse (373.3 [223-942.4]) , his-
tory of deep vein thrombosis (1296.7 [574.8-2018.5]), history
of coronary artery bypass graft (334.2 [175.3-727.6]), history
of asthma (303.7 [177.5-538.2]), history of pulmonary em-
boli (432.8 [248.9-439.7]), history of tuberculosis (391 [286-
496]), history of respiratory allergies (342.6 [216.1-469.2]),
history of cerebrovascular attack (333 [201-655.5]), history
of brain surgery (522.7 [297.9-1617.8]), history of migraine
(1116.7 [1116.7-1116.7]) and Alzheimer (356.7 [235.9-641.4])
and history of renal disease (479.4[204-846.9] in chronic kid-
ney disease, 503.8[175.3-685.1] in end-stage renal disease,
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Table 1 Total cost of hospitalization in COVID-19 patients (USD)
Variable Alive (n=735) Dead (n=256)
n Median IQR n Median IQR
Age (years)
10-24 12 309.0 (203.2 - 468.2) 0 — —
25-34 52 228.6 (177.7 - 489.3) 2 2484.3 (505.4 - 4463.1)
35-44 101 237.9 (161.1 - 373.3) 11 305.1 (152.7 - 2568.7)
45-54 146 253.7 (173.3 - 381.1) 20 302.1 (153.0 - 755.9)
55-64 136 250.8 (157.4 - 395.9) 48 368.6 (189.2 - 825.9)
≥ 65 288 267.2 (164.9 - 455.6) 175 396.8 (199.4 - 747.4)
Sex
Female 347 256.4 (173.3 - 413.3) 100 380.8 (190.1 - 753.4)
Male 388 252.5 (153.3 - 431.3) 156 379.9 (197.6 - 796.8)
Body mass index (kg/m2)
<18.9 7 266.2 (156.8 - 620.6) 10 353.7 (177.2 - 632.4)
18.9-24.9 223 237.9 (164.8 - 388.4) 85 383.3 (186.1 - 747.4)
25-29.9 330 260.2 (160.5 - 453.9) 102 368.8 (193.6 - 686.8)
30-39.9 153 260.7 (175.3 - 403.3) 55 442.8 (204.9 - 975.6)
≥ 40 22 321.6 (165.2 - 454.9) 4 247.2 (181.9 - 254.2)
Pregnancy
No 724 252.2 (164.9 - 422.5) 255 378.3 (193.6 - 761.2)
Yes 11 382.4 (282.4 - 786.7) 1 4463.1 (4463.1 - 4463.1)
Loss of consciousness during admission
No 691 249.1 (164.1 - 403.6) 207 363.3 (193.6 - 747.4)
Yes 44 458.3 (198.4 - 789.3) 49 468.5 (197.0 - 937.2)
Medical history
Previous COVID-19
No 731 253.2 (165.2 - 427.6) 255 383.3 (193.6 - 768.8)
Yes 4 467.5 (224.7 - 716.5) 1 239.0 (239.0 - 239.0)
Smoking
No 660 248.0 (160.8 - 414.2) 223 363.3 (189.9 - 773.7)
Cigarette 62 315.5 (223.0 - 592.6) 32 415.9 (242.8 - 594.7)
Hookah 13 200.5 (142.6 - 483.2) 1 993.7 (993.7 - 993.7)
Substance abuse
No 701 251.4 (163.4 - 426.7) 241 364.2 (193.6 - 747.4)
Opium 28 277.0 (221.1 - 368.4) 13 529.3 (324.4 - 784.7)
Other drugs 6 616.7 (201.6 - 764.7) 2 710.4 (445.2 - 975.6)
Alcohol use
No 724 253.0 (165.2 - 422.5) 252 377.2 (191.9 - 760.3)
Yes 11 373.3 (223.0 - 942.4) 4 634.8 (342.8 - 1727.3)
Hypertension
No 466 235.7 (158.8 - 376.4) 118 410.1 (217.4 - 810.1)
Yes 269 279.0 (175.2 - 488.0) 138 361.1 (184.8 - 736.0)
Hyperlipidemia
No 694 252.2 (165.2 - 413.3) 234 380.8 (196.6 - 759.4)
Yes 41 280.9 (175.3 - 568.5) 22 369.9 (156.5 - 784.7)
Diabetes mellitus
No 517 243.6 (158.4 - 406.7) 171 373.3 (186.1 - 768.8)
Yes 218 275.1 (182.6 - 476.2) 85 412.8 (218.0 - 761.2)
Aortic atherosclerosis
No 651 247.6 (160.4 - 413.3) 211 403.9 (186.1 - 802.3)
Yes 84 297.5 (201.0 - 481.5) 45 316.7 (218.4 - 538.7)
Coronary artery disease
No 607 247.7 (160.5 - 394.0) 190 377.2 (190.2 - 759.4)
Yes 128 289.7 (183.7 - 666.8) 66 384.9 (199.4 - 784.7)
Cardiomegaly
No 587 250.9 (160.3 - 426.7) 174 396.8 (193.6 - 772.7)
Yes 147 271.2 (175.3 - 432.8) 82 341.0 (195.6 - 736.0)
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Table 1 Total cost of hospitalization in COVID-19 patients (USD) (continued)
Variable Alive (n=735) Dead (n=256)
n Median IQR n Median IQR
Deep vein thrombosis
No 733 253.2 (165.2 - 426.7) 254 383.5 (195.6 - 768.8)
Yes 2 1296.7 (574.8 - 2018.5) 2 195.1 (78.3 - 311.8)
Coronary revascularization
No 659 248.9 (164.2 - 409.3) 215 396.8 (189.2 - 768.8)
CABG 38 334.2 (175.3 - 727.6) 19 304.0 (218.0 - 442.8)
Angioplasty 35 280.9 (195.0 - 592.6) 20 331.6 (198.2 - 946.1)
Family history of cardiovascular disease
No 658 250.8 (164.8 - 427.6) 237 376.1 (190.2 - 768.8)
Yes 77 273.5 (179.8 - 469.2) 19 420.1 (301.9 - 747.4)
Respiratory disorders
No 677 252.0 (164.9 - 409.3) 227 383.6 (190.2 - 773.7)
Asthma 49 303.7 (177.5 - 538.2) 24 427.5 (242.2 - 637.0)
Pulmonary emboli 3 432.8 (248.9 - 439.7) 1 177.2 (177.2 - 177.2)
Pneumonia 2 168.7 (122.7 - 214.7) 2 187.1 (141.6 - 232.5)
Tuberculosis 2 391.0 (286.0 - 496.0) 2 104.7 (56.7 - 152.8)
Allergy 2 342.6 (216.1 - 469.2) 0 — —
CNS disorders
No 673 250.9 (164.2 - 413.3) 211 364.2 (186.1 - 796.9)
Cerebral vascular accident 38 333.0 (201.0 - 655.5) 32 419.0 (199.0 - 605.3)
Seizure 7 194.4 (111.3 - 627.4) 4 384.6 (197.5 - 715.0)
Parkinson 3 100.5 (96.5 - 179.8) 3 442.8 (396.8 - 506.1)
Brain surgery 3 522.7 (297.9 - 1617.8) 2 271.4 (254.2 - 288.6)
Multiple sclerosis 10 223.9 (171.4 - 309.1) 2 279.4 (129.3 - 429.5)
Migraine 1 1116.7 (1116.7 - 1116.7) 1 650.2 (650.2 - 650.2)
Alzheimer disease
No 719 252.3 (165.0 - 418.3) 239 383.6 (193.6 - 772.7)
Yes 16 356.7 (235.9 - 641.4) 17 343.1 (235.2 - 589.6)
Kidney disease
No 672 248.0 (165.0 - 399.2) 226 385.0 (195.6 - 772.6)
Chronic kidney disease 36 479.4 (204.0 - 846.9) 27 324.4 (177.2 - 736.0)
End-stage renal disorders 15 503.8 (175.3 - 685.1) 3 641.3 (190.2 - 2514.0)
Kidney transplantation 3 373.5 (184.0 - 1025.5) 0 — —
Nephrotic syndrome 2 787.0 (39.0 - 1535.0) 0 — —
Nephrectomy 7 271.6 (121.9 - 832.1) 0 — —
Cancer
No 706 253.8 (165.3 - 427.6) 243 373.3 (193.6 - 761.2)
Yes 29 262.7 (143.0 - 429.6) 13 599.9 (231.5 - 927.1)
Thyroid disorders
No 684 254.5 (164.8 - 428.2) 240 368.8 (190.1 - 765.0)
Hypothyroidism 7 312.4 (175.9 - 714.5) 3 132.1 (123.5 - 196.1)
Hyperthyroidism 44 250.6 (200.0 - 393.7) 12 625.0 (384.9 - 742.3)
Immunosuppressive disorder
No 710 251.7 (164.9 - 426.7) 244 377.2 (190.1 - 773.2)
Yes 25 306.7 (225.5 - 474.7) 12 401.9 (290.3 - 510.2)
Congenital disorders
No 720 255.4 (165.3 - 427.2) 250 377.2 (193.6 - 759.4)
Yes 15 249.1 (142.9 - 771.6) 6 614.8 (342.5 - 936.8)
In-hospital cardiac complication
No 688 247.8 (164.2 - 398.8) 216 368.8 (187.7 - 693.5)
Myocardial infarction 27 561.9 (289.3 - 1151.8) 12 791.4 (298.8 - 920.7)
Cardiogenic shock 2 204.8 (141.7 - 267.9) 3 1050.6 (808.9 - 1715.4)
Heart failure 15 396.6 (207.0 - 657.9) 17 363.3 (217.1 - 904.5)
Sudden cardiac death — — — 8 351.8 (200.9 - 608.5)
Pericarditis 2 442.1 (352.7 - 531.5) 0 — —
Cardiac dysrhythmia
No 331 236.5 (156.5 - 382.4) 63 364.2 (218.0 - 569.7)
Yes 311 276.7 (177.8 - 486.2) 160 411.3 (196.4 - 833.3)
IQR: Interquartile range; CNS: Central nervous system
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Table 2 Associations of patient and hospital characteristics with hospitalization costs for COVID-19
Characteristics Alive Dead
Unadjusted Coef. (95% CI) P Unadjusted Coef. (95% CI) P
Age (years)
10-24 Reference -
25-34 0.21 (-0.57 - 0.99) 0.594 Reference
35-44 0.05 (-0.71 - 0.82) 0.890 1.48 (1.04 - 1.92) 0.000
45-54 0.03 (-0.73 - 0.78) 0.944 0.71 (0.30 - 1.12) 0.001
55-64 0.22 (-0.52 - 0.97) 0.559 0.24 (-0.23 - 0.71) 0.315
≥ 65 0.05 (-0.69 - 0.79) 0.891 0.03 (-0.36 - 0.42) 0.883
Sex
Female Reference Reference
Male 0.11 (-0.06 - 0.28) 0.193 0.06 (-0.24 - 0.37) 0.683
Body mass index (kg/m2)
<18.9 Reference Reference
18.9-24.9 -0.22 (-1.03 - 0.58) 0.586 0.14 (-0.74 - 1.03) 0.753
25-29.9 -0.04 (-0.84 - 0.75) 0.912 -0.01 (-0.90 - 0.88) 0.983
30-39.9 -0.06 (-0.87 - 0.75) 0.883 0.45 (-0.42 - 1.33) 0.312
≥ 40 0.01 (-0.89 - 0.91) 0.982 -0.90 (-4.30 - 2.50) 0.604
Pregnancy*
No Reference —
Yes 0.88 (0.58 - 1.18) <0.001 — —
Loss of consciousness during admission
No Reference Reference




Yes 0.18 (-0.77 - 1.14) 0.706 -0.96 (-7.02 - 5.10) 0.757
Smoking
No Reference Reference
Cigarette 0.21 (-0.04 - 0.47) 0.102 -0.31 (-0.88 - 0.25) 0.279
Hookah -0.02 (-0.69 - 0.65) 0.954 0.44 (-1.03 - 1.90) 0.559
Substance abuse
No Reference Reference
Opium 0.26 (-0.09 - 0.61) 0.149 0.10 (-0.51 - 0.71) 0.755
Other drugs 0.55 (0.00 - 1.11) 0.051 0.14 (-1.31 - 1.59) 0.851
Alcohol abuse
No Reference Reference
Yes 0.60 (0.21 - 0.99) 0.003 0.52 (-0.19 – 1.23) 0.153
Hypertension
No Reference Reference
Yes 0.18 (0.01 - 0.35) 0.040 -0.16 (-0.45 - 0.13) 0.293
Hyperlipidaemia
No Reference Reference
Yes 0.04 (-0.32 - 0.39) 0.834 0.10 (-0.38 - 0.58) 0.686
Diabetes mellitus
No Reference Reference
Yes 0.14 (-0.04 - 0.32) 0.119 -0.08 (-0.40 - 0.24) 0.612
Aortic atherosclerosis
No Reference Reference
Yes 0.20 (-0.03 - 0.43) 0.091 -0.21 (-0.66 - 0.23) 0.345
Coronary artery disease
No Reference Reference
Yes 0.39 (0.21 - 0.56) <0.001 -0.21 (-0.58 - 0.16) 0.268
Cardiomegaly
No Reference Reference
Yes 0.25 (0.07 - 0.43) 0.008 -0.07 (-0.39 - 0.25) 0.655
Coronary revascularization
No Reference Reference
CABG 0.44 (0.18 – 0.71) 0.001 -0.42 (-1.22 – 0.38) 0.302
Angioplasty 0.36 (0.06 - 0.65) 0.019 -0.20 (-0.83 – 0.43) 0.540
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Table 2 Associations of patient and hospital characteristics with hospitalization costs for COVID-19 (continued)
Characteristics Alive Dead
Unadjusted Coef. (95% CI) P Unadjusted Coef. (95% CI) P
Deep vein thrombosis
No Reference Reference
Yes 1.20 (0.71 – 1.70) <0.001 -1.16 (-6.41 – 4.08) 0.664
Family history of cardiovascular disease
No Reference Reference
Yes 0.22 (-0.01 - 0.46) 0.061 -0.20 (-0.86 - 0.46) 0.554
Respiratory disorders
No Reference Reference
Asthma 0.14 (-0.16 - 0.44) 0.373 -0.10 (-0.64 - 0.43) 0.706
Pulmonary emboli -0.04 (-1.43 - 1.35) 0.956 -1.28 (-9.47 - 6.91) 0.759
Pneumonia -0.83 (-4.61 - 2.94) 0.664 -1.23 (-6.71 - 4.26) 0.662
Tuberculosis 0.01 (-1.62 - 1.63) 0.995 -1.81 (-11.60 - 7.99) 0.718
Allergy -0.13 (-1.98 - 1.73) 0.894 —
CNS disorders
No Reference Reference
Cerebral vascular accident 0.25 (-0.06 - 0.55) 0.115 0.08 (-0.34 - 0.49) 0.719
Seizure -0.18 (-1.23 - 0.87) 0.742 -0.32 (-1.93 - 1.29) 0.699
Parkinson -1.12 (-5.24 - 3.00) 0.593 -0.33 (-2.22 - 1.55) 0.729
Brain surgery 0.74 (0.10 - 1.39) 0.023 -0.84 (-4.65 - 2.98) 0.667
Multiple sclerosis -0.19 (-1.08 - 0.70) 0.674 -0.81 (-4.51 - 2.90) 0.669
Migraine 1.06 (0.26 - 1.87) 0.010 0.04 (-2.22 - 2.29) 0.975
Alzheimer disease
No Reference Reference
Yes 0.35 (-0.06 - 0.77) 0.097 -0.17 (-0.84 - 0.51) 0.632
Kidney disease
No Reference Reference
Chronic kidney disease 0.62 (0.38 - 0.85) <0.001 -0.20 (-0.76 - 0.36) 0.484
End-stage renal disorders 0.64 (0.29 - 0.98) <0.001 0.57 (-0.19 - 1.34) 0.141
Kidney transplantation 0.37 (-0.61 - 1.34) 0.464 —
Nephrotic syndrome 0.76 (-0.04 - 1.57) 0.062 —
Nephrectomy 0.26 (-0.45 - 0.97) 0.471 —
Cancer
No Reference Reference
Yes -0.07 (-0.53 - 0.39) 0.765 -0.05 (-0.75 - 0.64) 0.879
Thyroid disorders
No Reference Reference
Hypothyroidism 0.04 (-0.79 - 0.87) 0.923 -1.43 (-7.00 - 4.14) 0.615
Hyperthyroidism -0.14 (-0.54 - 0.26) 0.497 -0.07 (-0.80 - 0.66) 0.847
Immunosuppressive disorder
No Reference Reference
Yes -0.02 (-0.49 - 0.46) 0.943 -0.27 (-1.15 - 0.61) 0.548
Congenital disorders
No Reference Reference
Yes 0.10 (-0.44 - 0.64) 0.720 0.60 (0.05 - 1.15) 0.033
In-hospital cardiac complication
No Reference Reference
Myocardial infarction 0.76 (0.52 - 0.99) 0.000 0.25 (-0.31 - 0.80) 0.381
Cardiogenic shock -0.60 (-3.65 - 2.44) 0.698 0.66 (-0.06 - 1.38) 0.073
Heart failure 0.08 (-0.50 - 0.65) 0.796 -0.19 (-0.90 - 0.52) 0.600
Sudden cardiac death — — -0.14 (-1.11 - 0.83) 0.775
Pericarditis 0.17 (-1.25 - 1.58) 0.817 —
Cardiac dysrhythmia
No Reference Reference
Yes 0.27 (0.09 - 0.46) 0.003 0.40 (-0.03 - 0.83) 0.067
* the analysis did not perform in dead people since there is only 1 observation
Coef.: Regression coefficient; CNS: Central nervous system
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373.5[184-1025.5] in kidney transplant patients, 787[39-1535]
in nephrotic syndrome and 271.6[121.9-832.1] in nephrec-
tomy patients) was higher than other patients. It’s also
worth noting that hospitalization costs increased with devel-
opment of cardiovascular complications during hospital stay
(561.9[289.3-1151.8] in myocardial infarction, 204.8[141.7-
267.9] in cardiogenic shock, 396.6[207-657.9] in heart failure
and 442.1[352.7-531.5] in pericarditis) (Table 1).
According to the conducted univariate analysis, pregnancy
(P<0.001), loss of consciousness (P<0.001), alcohol use
(P=0.003), hypertension (P=0.04), history of coronary artery
disease (P<0.001), history of cardiomegaly (P<0.001), his-
tory of coronary artery bypass surgery (P=0.001), history
of angioplasty (P=0.019), history of deep vein thrombosis
(P<0.001), history of brain surgery (P=0.023), history of mi-
graine (P=0.01), history of end-stage renal disease (P<0.001)
and history of chronic kidney disease (P<0.001) have possible
effecting factors of hospitalization costs. Regarding the com-
plications during hospitalization, it was shown that devel-
opment of myocardial infarction (P<0.001), sudden cardiac
death (P<0.001) and cardiac dysrhythmias (P=0.003) were re-
lated to an increase in hospitalization costs (Table 2).
Multivariate analysis showed that in living discharged pa-
tients, pregnancy (adjusted coefficient=1.05; 95% CI: 0.74,
1.36; P<0.001), loss of consciousness during hospitalization
(adjusted coefficient=0.53; 95% CI: 0.34, 0.73; P<0.001), his-
tory of substance abuse (adjusted coefficient=0.78; 95% CI:
0.22, 1.34); P=0.006), history of renal disease (adjusted coeffi-
cient=0.68; 95% CI: 0.46, 0.90; P<0.001), end-stage renal dis-
ease (adjusted coefficient=0.56; 95% CI: 0.21, 0.91; P=0.002),
history of brain surgery (adjusted coefficient=0.95; 95% CI:
0.41, 1.49; P=0.001), history of migraine (adjusted coeffi-
cient=1.29; 95% CI: 0.52, 2.06; P=0.001), and cardiomegaly
(adjusted coefficient=0.19; 95% CI: 0.01, 0.36; P=0.033) were
significantly related to hospitalization costs (Table 3).
3.3. Hospitalization costs in deceased COVID-19
patients
Evaluation of hospitalization costs of 256 deceased COVID-
19 patients showed that the greatest expenditure was for
hoteling and nursing services (median=109.4; IQR: 51.5-
271.1 USD), followed by drug (median=85.0; IQR: 37.8-
175.6 USD), physician services (median=72.0; IQR: 47.7-
106.2 USD), laboratory (median=71.5; IQR: 46.8-106.2 USD),
and imaging services (median=11.0; IQR: 7.0-23.5 USD) (Fig-
ure 1).
Table 1 summarizes the median and IQR of treatment costs
separated by the baseline and clinical variables of deceased
patients. Highest hospitalization costs were seen in the age
group of 25-34 (2484.3 [505.4-4463.1]). Also, in the group of
patients with history of cigarette smoking costs were con-
siderably higher (415.9[242.8-594.7). Alcohol (634.8[342.8-
1727.3]) and substance abuse (710.4 [445.2-975.6]), history
of migraine (650.2 [650.2-650.2]), end-stage renal disease
(641.3 [190.2-2514]), history of cancer (599.9 [231.5-927.1]),
Figure 1 Hospitalization costs for COVID-19 according to type of
cost and stratified by patients’ outcome
history of thyroid disease (132.1[123.5-196.1] in hypothy-
roidism and 625[384.9-742.3] in hyperthyroidism) and con-
genital diseases (614.8 [342.5-936.8]) were other factors that
were related to higher treatment costs. It is worth not-
ing that along with the incidence of cardiovascular com-
plications during hospitalization, treatment costs increased
(791.4[298.8-920.7] in myocardial infarction, 1050.6[808.9-
1715.4] in cardiogenic shock and 363.3 [217.1-904.5] in heart
failure.
Univariate analysis showed that age (P<0.001), congenital
diseases (P=0.033) as well as occurrence of cardiogenic shock
(P=0.073), and cardiac dysrhythmia (P=0.067) during hos-
pitalization where related to higher treatment costs in de-
ceased patients (Table 2). Based on multivariate analysis,
hospitalization costs were higher in lower age (adjusted coef-
ficient= -0.02; 95% CI: -0.03, -0.009; P<0.001) and showed di-
rect relationship with history of congenital diseases (adjusted
coefficient=0.53; 95% CI: 0.07, 0.98; P=0.024). Finally, occur-
rence of cardiac dysrhythmia (adjusted coefficient=0.45; 95%
CI: 0.01, 0.90; P=0.044) during hospitalization was associated
with higher costs in deceased patients (Table 4).
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Table 3 Multivariate analysis for assessment of independent factors associated with hospitalization cost in alive COVID-19 patients
Characteristics Adjusted Coef. (95% CI) P-value
Pregnancy
No Reference
Yes 1.05 (0.74, 1.36) <0.001
Loss of consciousness during admission
No Reference
Yes 0.53 (0.34, 0.73) <0.001
History of substance abuse
No Reference
Opium 0.30 (-0.01, 0.60) 0.053
Other drugs 0.78 (0.22, 1.34) 0.006
History of kidney disease
No Reference
Chronic kidney disease 0.68 (0.46, 0.90) <0.001
End-stage renal disorders 0.56 (0.21, 0.91) 0.002
History of CNS disorders
No Reference
Brain surgery 0.95 (0.41, 1.49) 0.001
Migraine 1.29 (0.52, 2.06) 0.001
Cardiomegaly
No Reference
Yes 0.19 (0.01, 0.36) 0.033
History of coronary revascularization
No Reference
Yes 0.23 (-0.02, 0.47) 0.072
In-hospital cardiac complication
No Reference
Myocardial infarction 0.71 (0.48, 0.93) <0.001
Cardiac dysrhythmia during hospitalization
No Reference
Yes 0.16 (-0.02, 0.47) 0.067
Alcohol abuse
No Reference
Yes 0.45 (-0.03, 0.94) 0.069
Diabetes mellitus
No Reference
Yes 0.14 (-0.02, 0.32) 0.096
Coef.: Regression coefficient; CNS: Central nervous system
Table 4 Multivariate analysis for assessment of independent factors associated with hospitalization cost in dead COVID-19 patients
Characteristics Adjusted Coef. (95% CI) P-value
Age -0.02 (-0.03, -0.009) <0.001
History of congenital disorders
No Reference
Yes 0.53 (0.07, 0.98) 0.024
In-hospital cardiac complication
No Reference
Cardiogenic shock 0.70 (-0.02, 1.42) 0.055
Cardiac dysrhythmia during hospitalization
No Reference
Yes 0.45 (0.01, 0.90) 0.044
Coef.: Regression coefficient; CNS: Central nervous system
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4. Discussion
The current retrospective cohort study evaluated the associa-
tion between factors influencing hospitalization costs. Based
on our findings, a history of heart disease and occurrence of
cardiovascular complications during hospitalization results
in an increased cost of COVID-19 patients. This along with
other findings that point to dangerous cardiovascular com-
plications of COVID-19, indicate the importance of paying
more attention to cardiovascular complications of COVID-
19. Alongside these complications, loss of consciousness
during hospitalization, history of brain surgery, history of re-
nal disease, migraine, and pregnancy are other independent
factors influencing hospitalization costs.
Underlying diseases predispose patients to develop severe
forms of COVID-19, and loss of consciousness and cardiac
dysrhythmias demonstrate severe condition of patients with
increase potential risk of hospitalization and need for inten-
sive care unit admission (12-15). There is a paucity in stud-
ies that have tried to evaluate the relationship of COVID-19
patients’ mortality and hospitalization costs; therefore, it is
not possible at the moment to conclude whether COVID-19
mortality is associated with higher hospital costs or not. De-
veloping a severe form of COVID-19 on one hand increases
mortality rates that can result in reduced duration of hospi-
talization, while on the other hand can increase the amount
of total costs by increasing the need for admission in inten-
sive care units and patient hoteling costs (16, 17).
In this study, analyses were stratified based on patients’ dis-
charge status (alive or deceased) in order to remove the effect
of outcome. We observed that underlying cardiovascular dis-
eases were associated with higher costs of treatment in living
discharged patients, but not in deceased patients.
Our study results appoint equal importance to underlying re-
nal diseases and cardiovascular diseases in increasing hos-
pitalization costs; this finding is in alignment with recent
studies on risk factors of severe COVID-19 infection that
have concluded history of renal disease is a stronger risk fac-
tor than chronic pulmonary diseases and therefore its im-
portance might have been underestimated in previous re-
searches (18).
Based on guidelines of NIH, pregnant women infected with
COVID-19 with indications for hospitalization, should be
hospitalized in a ward where both mother and the fetus can
be monitored and isolated if needed (19, 20). As most stud-
ies on COVID-19 have excluded pregnant and breastfeeding
women from study population, more studies are needed for
evaluating the effects of COVID-19 on this population and its
hospitalization costs.
Loss of consciousness can be due to cardiac or brain injuries
and poisoning (21). COVID-19 can result in loss of con-
sciousness by causing encephalopathy, pulmonary involve-
ment and hypoxia, and cardiac ischemic diseases (22). Ac-
cording to the guideline of COVID-19 hospitalization, loss of
consciousness is an important indication for intensive care
unit admission (23); therefore, it is expected that loss of con-
sciousness would increase hospitalization costs dramatically.
One of the factors that is directly related to increased hospi-
tal costs is the length of hospital stay. Nevertheless, what is
important about it is that the length of stay is practically the
main part of the cost of hoteling. Therefore, practically the
length of hospital stay is a part of the response variable, i.e.,
hospital costs. The cost of hoteling depends on the length of
stay, and the longer the stay, the higher the cost of hoteling.
In other words, the length of hospital stay is concealed in to-
tal hospital cost and bringing this variable as a separate factor
in the model causes bias in the model. Since once the depen-
dent costs (hoteling) are included in the total cost calcula-
tions (in the response variable) and once again the length of
hospital stay within the model is entered as a possible influ-
ential factor (independent variable); accordingly, the effect of
hospital stay is falsely overestimated.
5. Limitations
This study had some limitations. In assessing the relation-
ship between some underlying diseases and costs, the num-
ber of patients with that special comorbidity has been low,
which can potentially decrease the power of our analyses.
Also, due to the possibility of bias in self-reporting the his-
tory of addiction and alcohol abuse in patients, and also lack
of definitive diagnostic tests for confirmation of underlying
diseases, there could have been some error in our analyses
on that matter; therefore, more comprehensive prospective
studies are required for evaluating the effect of underlying
disorders on COVID-19 infection and hospitalization costs.
Finally, the hospital in which this study was conducted, is a
teaching public hospital that has cost rates based on govern-
ment tariffs; therefore, other study is needed for evaluating
costs in private hospitals.
6. Conclusion
The median cost for a COVID-19 patient hospitalized in
a teaching public hospital in Tehran, Iran was 271.1 USD.
Hoteling services and drug made up the majority of costs.
History of cardiovascular diseases and occurrence of new
cardiovascular complications during hospitalization were
the most important factors influencing costs. Along with
these factors, pregnancy, loss of consciousness, history of al-
cohol abuse, and underlying renal diseases were other in-
dependent factors that were associated with higher costs of
treatment in COVID-19 patients.
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